Cognoptix

Focus: Cognoptix is an eye-scanning diagnostic company developing novel biomarkers for neurological disease detection, particularly focused on cognitive impairment. The company is based in Marlborough, MA and operates as a pre-revenue diagnostic innovator.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Cognoptix

AI assessmentNot Hiring

No open roles listed right now. Follow Cognoptix to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Sapphire II

Mild Cognitive Impairment

Phase 1

Clinical Trials (1)

NCT02928211Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations

Phase 1

Help build intelligence for Cognoptix

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

First-mover advantage in ophthalmologic biomarkers for neurodegenerative disease, a growing diagnostic category with significant unmet need
Early-stage pipeline with Phase 1 program (Sapphire II) targeting mild cognitive impairment, offering ground-floor opportunity to shape clinical development strategy
Innovative platform technology in eye scanning positions company at intersection of ophthalmology, neurology, and digital health

Watch Out For

Zero active job openings and undisclosed employee count suggest minimal near-term hiring; company stage and funding status unknown create visibility gaps
Single Phase 1 program with no marketed products means revenue is non-existent and clinical value proposition remains unproven; high technical and commercial risk

Generated by Claude from Cognoptix's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

1 pipeline

Marketed

Pipeline